Φορτώνει......
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
BACKGROUND: Tenofovir alafenamide (TAF) is a novel tenofovir prodrug with improved renal and bone safety compared with TDF-containing regimens. We report the 48 week safety and efficacy of a once-daily single tablet regimen of elvitegravir 150 mg (E), cobicistat 150 mg (C), emtricitabine 200 mg (F),...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Acquir Immune Defic Syndr |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
JAIDS Journal of Acquired Immune Deficiency Syndromes
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4804743/ https://ncbi.nlm.nih.gov/pubmed/26627107 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000000908 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|